Mike Clayman, M.D., Chief Executive Officer and Co-Founder, Flexion Therapeutics brings us up to speed on the work at Flexion developing and commercializing new treatments for musculoskeletal disorders (MSDs) including osteoarthritis (OA) knee pain. Mike also talks about how the company has been adapting to the COVID-19 pandemic to get their drug Zilretta out to patients in need.
@FlexionInc #musculoskeletaldisorder #OAK #kneepain #osteoarthritisofknee #MSD #COVID19
FlexionTherapeutics.com
Download the transcript here
Empowered Patient Podcast